Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction
NCT ID: NCT02911337
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2015-08-31
2018-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.
NCT05942287
Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study
NCT04942548
Weight Loss as Treatment in Heart Disease
NCT02105805
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878
Bariatric Surgery Evaluation and Assessment of Treatment Efficacy - Intervention Trial
NCT06065124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lifestyle modification
Lifestyle modification
lifestyle modification
Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lifestyle modification
Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to perform 6 minute hall walk test
* Left Ventricular ejection fraction \>45%
* Diagnosis of heart failure with preserved ejection fraction (HFpEF) ; confirmation of HFpEF based on 1 major or 3 minor criteria listed below.
Major:
1. Elevated BNP \>200
2. cardiogenic pulmonary edema
3. Pulmonary capillary wedge pressure at rest \>15 mmhg or with exercise \>25 mmhg using invasive right heart pressure measurement
Minor:
1. Left atrial enlargement (volume \>68 ml)
2. increased left ventricular wall thickness (\>1.1cm) by echocardiography
3. E/e' \>15
4. intermediate level of BNP, 60-199
Exclusion Criteria
* severe chronic obstructive pulmonary disease (oxygen or steroid dependent)
* recurrent major depression. presence or history of suicide behavior, and current substantial depressive symptoms. Antidepressant drugs are allowed if the dose has been stable for 3 months
* other major psychiatric illness (schizophrenia, bipolar, dementia)
* significant hepatic dysfunction
* untreated hypothyroidism or hyperthyroidism
* history of drug or alcohol abuse or dependency within the past 12 months
* acute coronary syndrome without revascularization in the past 12 months
* acute coronary syndrome with revascularization in the past 6 months
* Cerebrovascular accident or transient ischemic attack in the past 6 months
* cancer or terminal illness with life expectancy \< 3 years
* history of medical noncompliance
* significant anemia (hgb \<9)
* life threatening or uncontrolled arrhythmia
* hemodynamically relevant valvular heart disease
* infiltrative heart disease including cardiac amyloidosis, sarcoidosis, Fabry's disease
* genetic hypertrophic cardiomyopathy
* significant pericardial disease
* clinically relevant neuromuscular disease
* pregnant or may become pregnant in the next 6 months
* prior major organ transplant or intent to transplant ( on the transplant list)
* pacemaker dependant
* clinically significant congenital heart disease that may be cause of symptoms
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MUSC Gazes Research Institue
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
El Hajj EC, El Hajj MC, Sykes B, Lamicq M, Zile MR, Malcolm R, O'Neil PM, Litwin SE. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 Nov 2;10(21):e022930. doi: 10.1161/JAHA.121.022930. Epub 2021 Oct 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WTLSSCHF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.